Another PBM Favors Sandoz And Boehringer On Adalimumab
Humira Rivals Hyrimoz And Cyltezo Get Preferred Status From Express Scripts
Express Scripts has followed Optum Rx’s lead by awarding preferred status to Humira biosimilars from Sandoz and Boehringer Ingelheim.
You may also be interested in...
Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.
With several Humira biosimilars entering the US market, price competition was fiercer and faster than expected in the second half of 2023, according to Cencora. The former AmerisourceBergen firm’s biosimilars experts Brian Biehn and Connor Nell touch on topics including adalimumab trends, ophthalmology and oncology biosimilars, and the Inflation Reduction Act in a Q&A with Generics Bulletin.
The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.